S. Pleus is an employee of the Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm (IfDT).A. Tytko is a diabetologist in private practice and received consulting fees from Roche as part of a project of the Association of Registered Diabetologists of Lower Saxony (VNDN); lecture fees and reimbursement of travel expenses from the companies Lilly, Novo Nordisk, Sanofi.R. Landgraf declares the following potential conflicts of interest: Advisory boards: Lilly Deutschland, Novo Nordisk Pharma; lecture fees: Lilly Deutschland, Novo Nordisk Pharma. Other activities: Curator of the German Diabetes Foundation, member of the steering group for the development and updating of the National Healthcare Guidelines on Diabetes.L. Heinemann is a shareholder of the Profil Institute for Metabolism Research GmbH, Neuss. He is an advisor for many companies which develop new diagnostic and therapeutic options for diabetes therapy.C. Werner declares the following potential conflicts of interest: Travel reimbursement from Novartis Oncology, most recently in 2018. Shareholdings in Medtronic and Novo Nordisk.D. Müller-Wieland declares the following potential conflicts of interest: Member of advisory boards and lecture fees: Amarin, Amgen, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, MSD, AstraZeneca, Novo Nordisk, Novartis, Sanofi.A.G. Ziegler received consulting and lecture fees from Provention Bio and Sanofi. U.A. Müller declares no conflicts of interest. Public declaration of interests: https://www.akdae.de/Kommission/Organisation/Mitglieder/DoI/Mueller.pdfG. Freckmann is Medical Director and Managing Director of the IfDT, which carries out clinical studies e.g. with medical devices for diabetes therapy on its own initiative and on behalf of various companies. G.F./IfDT have received speakers’ honoraria or consulting fees in the last 3 years Abbott, Berlin Chemie, Boydsense, Dexcom, Lilly Deutschland, Novo Nordisk, Perfood, Pharmasens, Roche, Sinocare, Terumo, Ypsomed.E. Schleicher declares no conflicts of interest.H. Kleinwechter declares no conflict of interest with regard to this clinical practice guideline.M. Nauck has received lecture fees from Amgen, Novartis, Synlab, Tosoh Bioscience, Radiometer, Roche Diagnostics, Technopath. Advisory board: Novartis.A. Petersmann has received consulting and lecture fees from Tosoh Bioscience, Radiometer, Roche Diagnostics, Nova Biomedical, Siemens Healthineers, Technopath.